Skip to main content
SpringerLink
Log in

Nusinersen has favourable safety profile in paediatric patients

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Darras BT, et al. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs : 23 Aug 2019. Available from: URL: https://doi.org/10.1007/s40263-019-00656-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nusinersen has favourable safety profile in paediatric patients. Reactions Weekly 1768, 11 (2019). https://doi.org/10.1007/s40278-019-66696-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-66696-3

Search

Navigation